Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening.

CONCLUSION: These promising drugs could inhibit the replication of the virus; hence, we suggest the repurposing of these compounds for thetreatment of COVID-19. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. However, the assessment of these potential inhibitors as clinical drugs involves further in vivo tests for these drugs.
PMID: 32748740 [PubMed - as supplied by publisher]

Source: Combinatorial Chemistry and High Throughput Screening - July 29, 2020 Category: Chemistry Authors: Chtita S, Belhassan A, Aouidate A, Belaidi S, Bouachrine M, Lakhlifi T Tags: Comb Chem High Throughput Screen Source Type: research